Department of Hepatobiliary, HCC Research Center for Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Biosci Trends. 2021 Jul 6;15(3):142-147. doi: 10.5582/bst.2021.01083. Epub 2021 Mar 14.
Hepatocellular carcinoma (HCC) is a common malignant tumor with a high morbidity and mortality in China and elsewhere in the world. Due to its tumor heterogeneity and distant metastasis, patients with HCC often have a poor prognosis. A surgical treatment such as a radical hepatectomy is still the treatment of choice for patients with HCC in current clinical practice. However, the high rate of recurrence and rate of metastasis after surgery diminishes the survival of and prognosis for these patients. In an era of targeted therapy and immunotherapy, the surgical treatment of HCC must change. This review focuses on the definition, feasibility, and criteria with which to evaluate neoadjuvant therapy for HCC in order to provide a new perspective on surgical treatment of HCC.
肝细胞癌（HCC）是一种常见的恶性肿瘤，在中国和世界其他地区发病率和死亡率都很高。由于其肿瘤异质性和远处转移，HCC 患者的预后通常较差。根治性肝切除术等手术治疗仍然是目前临床实践中 HCC 患者的首选治疗方法。然而，手术后的高复发率和转移率降低了这些患者的生存率和预后。在靶向治疗和免疫治疗时代，HCC 的手术治疗必须改变。本综述重点讨论 HCC 新辅助治疗的定义、可行性和评估标准，以期为 HCC 的手术治疗提供新视角。
